<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861809</url>
  </required_header>
  <id_info>
    <org_study_id>111809</org_study_id>
    <nct_id>NCT00861809</nct_id>
  </id_info>
  <brief_title>The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients With Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacodynamic effects (gastric emptying),&#xD;
      safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic&#xD;
      patients with gastroparesis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastric emptying, as measured by the 13C octanoic acid breath test (Gastric half emptying time (t1/2b), Duration of the lag time (tlag), Gastric evacuation coefficient (GEC))</measure>
    <time_frame>1.5 h post dose to 5.5 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of GSK962040 (Change from baseline and number of patients outside the normal range for blood pressure, heart rate, 12-lead ECG parameters)</measure>
    <time_frame>2 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of GSK962040: Cmax, Tmax, AUC(0-t), AUC(0-inf) for single-dose, CL/F, V/F, and, if possible, half-life</measure>
    <time_frame>24 h post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of GSK962040 (Adverse events)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of GSK962040 (Change from baseline in clinical chemistry and hematology parameters)</measure>
    <time_frame>24 h post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bowel movement parameters (Time to first bowel movement after first dose, Bowel movement count, Stool consistency (Bristol Stool Form scale))</measure>
    <time_frame>24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK/PD relationship of PP, plasma glucagon, GLP-1, and ghrelin after a single dose of GSK962040.</measure>
    <time_frame>0-6 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>24 h post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food intake</measure>
    <time_frame>24 h post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Period 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK962040 25 mg</intervention_name>
    <description>25 mg</description>
    <arm_group_label>Cohort 1 Period 1</arm_group_label>
    <arm_group_label>Cohort 1 Period 2</arm_group_label>
    <arm_group_label>Cohort 1 Period 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo comparator</description>
    <arm_group_label>Cohort 1 Period 1</arm_group_label>
    <arm_group_label>Cohort 1 Period 2</arm_group_label>
    <arm_group_label>Cohort 1 Period 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK962040 50 mg</intervention_name>
    <description>50 mg</description>
    <arm_group_label>Cohort 1 Period 1</arm_group_label>
    <arm_group_label>Cohort 1 Period 2</arm_group_label>
    <arm_group_label>Cohort 1 Period 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK962040 1250 mg</intervention_name>
    <description>125 mg</description>
    <arm_group_label>Cohort 1 Period 1</arm_group_label>
    <arm_group_label>Cohort 1 Period 2</arm_group_label>
    <arm_group_label>Cohort 1 Period 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Controlled Type 1 Diabetes Mellitus (glucose &lt; 250 mg/dL) with onset &lt; 30 years of&#xD;
             age.&#xD;
&#xD;
          -  Male or female between 18 and 70 years of age, inclusive.&#xD;
&#xD;
          -  Patient has documented diagnosis of moderate to severe gastroparesis (&gt; 30% at 2 h as&#xD;
             determined by scintigraphy; or t1/2b &gt; 109 min as determined by 13C-octanoic acid&#xD;
             breath test). All of the following apply:&#xD;
&#xD;
          -  Confirmed delayed gastric emptying (properly conducted gastric emptying assessments&#xD;
             within last 6 months acceptable) AND a minimum 3 month history of relevant symptoms&#xD;
             for gastroparesis (e.g., chronic postprandial fullness, postprandial nausea, vomiting)&#xD;
&#xD;
          -  A female patient is eligible to participate if she is of:&#xD;
&#xD;
          -  Non-childbearing potential&#xD;
&#xD;
          -  Child-bearing potential and agrees to use contraception for at least 4 days following&#xD;
             the last dose of study medication.&#xD;
&#xD;
          -  Male patients must agree to use contraception from the time of the first dose of study&#xD;
             medication through at least 4 days after the last dose of study medication.&#xD;
&#xD;
          -  Body weight ≤110 kg and BMI &lt; 32.0 kg/m2 (inclusive).&#xD;
&#xD;
          -  Patient has never had a gastrectomy, nor major gastric surgical procedure or any&#xD;
             evidence of bowel obstruction within the previous 12 months&#xD;
&#xD;
          -  Dosage of any concomitant medications has been stable for at least 3 weeks, except for&#xD;
             routine adjustments in daily insulin treatments&#xD;
&#xD;
          -  HbA1c level is ≤ 10.0%&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; or equal to 50 ml/min&#xD;
&#xD;
          -  QTcB or QTcF &lt; 450 msec or QTc&lt;480msec in patients with Bundle Branch Block based on&#xD;
             single or average QTc value of triplicate values obtained over a brief recording&#xD;
             period.&#xD;
&#xD;
          -  AST, ALT, alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin &gt;1.5xULN is&#xD;
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%)&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has acute severe gastroenteritis&#xD;
&#xD;
          -  Patient has a gastric pacemaker&#xD;
&#xD;
          -  Patient is on chronic parenteral feeding&#xD;
&#xD;
          -  Patient has daily persistent severe vomiting&#xD;
&#xD;
          -  Patient has pronounced dehydration&#xD;
&#xD;
          -  Patient has had clinical diabetic ketoacidosis in last 4 weeks&#xD;
&#xD;
          -  Patient has a history of eating disorders (anorexia nervosa, binge eating, bulimia)&#xD;
&#xD;
          -  Use of medications potentially influencing upper gastrointestinal motility or appetite&#xD;
             within one week of the study (e.g., prokinetic drugs, macrolide antibiotics&#xD;
             (erythromycin))&#xD;
&#xD;
          -  Patient is taking opiates.&#xD;
&#xD;
          -  Use of prohibited medications listed in Section 9.2 within the restricted timeframe&#xD;
             relative to the first dose of study medication.&#xD;
&#xD;
          -  History or presence of clinically significant gastro-intestinal, hepatic or renal&#xD;
             disease or other condition known to interfere with the absorption, distribution,&#xD;
             metabolism or excretion of drugs.&#xD;
&#xD;
          -  Presence of thyroid dysfunction (NOTE: patients with abnormal TSH at&#xD;
             screening/baseline are not eligible. Patients with a history of hypothyroidism on a&#xD;
             stable dose of thyroid replacement therapy are eligible to participate in the study).&#xD;
&#xD;
          -  The patient has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period.&#xD;
&#xD;
          -  Pregnant females as determined by positive serum or urine hCG test (from the first&#xD;
             urine of the day) at screening or prior to dosing.&#xD;
&#xD;
          -  Lactating or pregnant females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Patients deemed unable to comply with the procedures outlined in the protocol may be&#xD;
             excluded at the Investigator's discretion.&#xD;
&#xD;
          -  For male volunteers: An unwillingness of the male patient to comply with the&#xD;
             contraception requirements listed in Section 8.1, from the time of the first dose of&#xD;
             study medication until at least 4 days following administration of the last dose of&#xD;
             study medication.&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <disposition_first_submitted>March 22, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>March 22, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 29, 2012</disposition_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>single dose</keyword>
  <keyword>gut motility</keyword>
  <keyword>Type I Diabetes Mellitus patients</keyword>
  <keyword>tolerability</keyword>
  <keyword>phase II</keyword>
  <keyword>13C octanoic acid breath test</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>gastric emtpying</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111809</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111809</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111809</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111809</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111809</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111809</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111809</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>March 27, 2017</submitted>
    <returned>May 9, 2017</returned>
    <submitted>September 15, 2017</submitted>
    <submission_canceled>August 15, 2018</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

